In contrast, in our research the MYD88 L265P mutation was detected in half of the patients with non-GCB DLBCL with nodal involvement, while the remaining mutation was present in an immune-privileged site: the CNS (brain). Here, MYD88 is linked to diffuse large B-cell lymphoma.